Abstract 3947
Background
Liposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan which prolongs circulation of irinotecan and its active metabolite SN-38. This analysis describes the population pharmacokinetics (PK) of nal-IRI in patients with various tumour types, including untreated mPC.
Methods
Plasma concentration data for total irinotecan (tIRI) and SN-38 from an open-label, phase 2 study of nal-IRI plus 5-fluorouracil/leucovorin and oxaliplatin in patients with untreated mPC (NCT02551991; N = 48) were pooled with data from six other nal-IRI studies (five phase 1/2, one phase 3) in various tumour types. Data from overall 440 patients were used in the population PK model for tIRI and SN-38 after nal-IRI administration. PK parameters were estimated with non-linear mixed effects modelling. The adequacy of the model was assessed based on the uncertainty of parameter estimates, and on advanced evaluation methods such as visual predictive check. Potential covariates such as patient demographics and genotype were investigated to examine inter-individual variability.
Results
tIRI is described by a two-compartment model with first-order elimination. SN-38 is formed directly by a first-order constant from the central compartment of nal-IRI or after using a transit compartment. In the pooled population (N = 440), clearance was 0.1 L/h and 150 L/h for tIRI and SN-38, respectively. Central and peripheral volumes of distributions for tIRI were 4 L and 0.4 L, respectively. Consistent with previous data, tIRI clearance was 80% higher in patients of Asian ethnicity (n = 154/440) than other populations. Increasing bilirubin levels were associated with lower SN-38 clearance, and tIRI and SN-38 clearances were 20% lower in females than males. The UGT1A128 7/7 homozygous genotype (6% of the study population) had no statistically significant impact on SN-38 clearance. Model evaluation was satisfactory for both tIRI and SN-38.
Conclusions
The PK of nal-IRI and SN-38 in patients with mPC is well described by the population model. The results suggest that UGT status has no impact on the PK of nal-IRI.
Clinical trial identification
Editorial acknowledgement
Oxford PharmaGenesis, Oxford, UK for providing editorial support, which was sponsored by Ipsen, Abingdon, UK.
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
T. Macarulla: Honoraria (institution): Shire Pharmaceuticals; Honoraria (institution): Roche; Honoraria (institution): Tesaro; Honoraria (institution): Baxter; Honoraria (institution), Travel / Accommodation / Expenses: Sanofi; Honoraria (institution): Celgene; Honoraria (institution): QED Therapeutics; Honoraria (institution): Genzyme Europe; Honoraria (institution): Baxalta; Honoraria (institution), Travel / Accommodation / Expenses: Bayer; Honoraria (institution): Incyte; Honoraria (institution): Genzyme; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: H3 Biomedicine. K. Brendel: Full / Part-time employment: Ipsen. Z.A. Wainberg: Advisory / Consultancy: Lilly; Advisory / Consultancy: Merck; Advisory / Consultancy: BMS; Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: Ipsen. F. Dayyani: Advisory / Consultancy: Array; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai; Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sirtex. B. Zhang: Full / Part-time employment: Ipsen. B. Belanger: Full / Parttime employment: Ipsen. Y. Moore: Full / Part-time employment: Ipsen. A. Pedret-Dunn: Full / Parttime employment: Ipsen. F. Maxwell: Full / Part-time employment: Ipsen. A. Dean: Advisory / Consultancy, Non-paid: Shire; Advisory / Consultancy, Non-paid: Specialised Therapeutics Australia; Travel / Accommodation / Expenses, Grant: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract